Form 4: X4 Pharma CFO Granted Significant Equity Awards

X4 Pharmaceuticals' Chief Financial Officer, David Kirske, was granted 193,254 restricted stock units and 1,426,049 stock options as part of his compensation.

Summary

• David Kirske, Chief Financial Officer of X4 Pharmaceuticals, Inc. (XFOR), was granted new equity awards.
• The awards include 193,254 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted on August 14, 2025, at a price of $0.
• The RSUs will vest one-third on February 12, 2026, with the remainder vesting in equal quarterly installments over the subsequent 12 months, contingent on continued service and approval at the Issuer's 2026 Annual Meeting of Stockholders.
• Additionally, Mr. Kirske was granted 1,073,249 stock options with an exercise price of $1.42, granted on August 12, 2025, and expiring on August 12, 2035.
• He also received 352,800 stock options with an exercise price of $3.14, granted on August 14, 2025, and expiring on August 14, 2035.
• The stock options will vest one-half on February 12, 2026, with the remainder vesting in equal monthly installments over the subsequent 12 months, subject to continued service.
• A significant portion (one-half) of the shares subject to the options may vest immediately upon achieving certain performance-based milestones prior to February 12, 2026.

Sentiment

Score: 7

Explanation: The filing indicates significant equity grants to a key executive, which is generally positive for executive retention and alignment with shareholder interests. However, the contingency of RSU approval and the routine nature of the filing prevent a higher score.

Positives

• The grants align the Chief Financial Officer's interests with those of shareholders through equity ownership.
• The significant equity awards serve as an incentive for long-term retention and performance of a key executive.
• Performance-based vesting conditions for stock options could motivate the achievement of strategic company goals.

Negatives

• The vesting of restricted stock units is contingent upon approval at the Issuer's 2026 Annual Meeting of Stockholders, introducing a potential uncertainty.
• The grants represent potential future dilution for existing shareholders as the RSUs vest and options are exercised.

Risks

• The vesting of 193,254 restricted stock units is contingent upon approval at the Issuer's 2026 Annual Meeting of Stockholders.
• The vesting of stock options is subject to the Reporting Person continuing to provide services through the specified vesting dates.
• One half of the stock options' vesting is tied to the achievement of certain performance-based milestones prior to February 12, 2026, which may or may not be met.

Future Outlook

The equity awards are structured with future vesting schedules extending into 2026 and beyond, contingent on continued service and, for RSUs, shareholder approval at the 2026 Annual Meeting. Performance-based milestones could accelerate the vesting of half of the stock options prior to February 12, 2026.

Industry Context

This filing represents a routine executive compensation event, common across publicly traded companies, where equity awards are used to incentivize and retain key management personnel. The specific terms reflect the company's compensation strategy within the biotechnology or pharmaceutical sector.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to David Kirske, the Chief Financial Officer, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting of RSUs and exercise of options, but also increased alignment of management's interests with shareholder value creation.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to executive incentives.
• Management: Significant long-term incentives tied to company performance and continued service.

Next Steps

• Continued service of the Chief Financial Officer through vesting dates.
• Achievement of certain performance-based milestones prior to February 12, 2026, for accelerated option vesting.
• Approval of the RSU grant at the Issuer's 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

X4 Pharmaceuticals, XFOR, SEC Form 4, Stock Options, Restricted Stock Units, Executive Compensation, Equity Grant, CFO, Insider Trading, Beneficial Ownership